Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

Table of Contents

November 1, 2019; Volume 60,Issue 11

Cover image

Cover image expansion

FEATURED ARTICLE

Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. Jorge Carrasquillo et al. See page 1517.

Refining PSMA targeting: setting molar activity levels to minimize normal tissue adverse effects. Fumihiko Soeda et al. See page 1594.

Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine: 60 (11)
Journal of Nuclear Medicine
Vol. 60, Issue 11
November 1, 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author

Issue highlights

  • Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody
  • Impact of 18F-PSMA-1007 Uptake in Prostate Cancer Using Different Peptide Concentrations: Preclinical PET/CT Study on Mice
  • Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics
  • Radioactive Iodine Treatment and Cancer Mortality in Hyperthyroid Patients: Questioning Standard Clinical Practice Requires Indisputable Scientific Data
Sign up for alerts

Jump to

  • This Month in JNM
  • Discussions with Leaders
  • Editorial
  • Hot Topics
  • The State of the Art
  • Continuing Education
  • Oncology
    • Clinical
      • FEATURED ARTICLE OF THE MONTH
      • INVITED PERSPECTIVE
    • Basic
  • Theranostics
    • Clinical
    • Basic
      • FEATURED BASIC SCIENCE ARTICLE
  • Endocrinology
    • Clinical
  • Neurology
    • Clinical
  • Radiochemistry
    • Basic
  • Molecular Imaging
    • Basic
  • Physics and Instrumentation
  • Errata
  • SNMMI Newsline
  • Most Cited
  • Most Read
Loading
  • Total-Body PET Multiparametric Imaging of Cancer Using a Voxelwise Strategy of Compartmental Modeling
  • Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients
  • 68Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the 68Ga-FAPI PET Prospective Observational Trial
  • MIRD Pamphlet No. 27: MIRDcell V3, a Revised Software Tool for Multicellular Dosimetry and Bioeffect Modeling
  • Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results
More...
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire